Novel liposomal gefitinib (L-GEF) formulations

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2919-2923

  Zhou, Xiaoju ^a,b   Yung, Bryant ^b   Huang, Yifei ^b,c   Li, Hong ^b   Hu, Xianming ^a   Xiang, Guangya ^c   Lee, Robert J ^b  

^a WUHAN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer; Drug delivery; Gefitinib; HP CD; Liposome; Remote loading

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHOLESTEROL; GEFITINIB; LIPOSOMAL GEFITINIB; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CELL LINE, TUMOR; DRUG STABILITY; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED ICR; PARTICLE SIZE; QUINAZOLINES;

EID: 84865701956     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ and Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002. (Pubitemid 35204731)
2. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063, 2000. (Pubitemid 30305105)
3. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000. (Pubitemid 32110433)
4. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B and Hylton NM: Improved tumor vascular function following high dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging 26: 1618-1625, 2007. (Pubitemid 350291291)
5. Gridelli C, Marinis FD and Maio MD: Gefitinib as first-line treatment for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 71: 249-257, 2011.
6. Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F and Morabito A: Gefitinib in non-small cell lung cancer. J Biomed Biotechnol 2011: 815269, 2011.
7. Cheng X, Li W, Hu X, Geng Y, Wang R, Yin Y and Shu Y: Effect of gefitinib challenge to initial treatment with non-small cell lung cancer. Biomed Pharmacother 65: 542-546, 2011.
8. Siegel-Lakhai WS, Beijnen JH and Schellens JHM: Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®). Oncologist 10: 579-589, 2005. (Pubitemid 41429121)
9. Phillip Lee YH, Sathigari S, Jean Lin YJ, Ravis WR, Chadha G, Parsons DL, Rangari VK, Wright N and Babu RJ: Gefitinibcyclodextrin inclusion complexes: physico-chemical characteri-zation and dissolution studies. Drug Dev Ind Pharm 35: 1113-1120, 2009.
10. Liu J, Brahmer J, Messersmith W, Hidalgo M and Baker SD: Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drug 24: 291-297, 2006.
11. Voinea M and Simionescu M: Desigtning of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med 6: 465-474, 2002. (Pubitemid 44146431)
12. Clerc S and Barenholz Y: Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta 1240: 257-265, 2005.
13. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y and Naparstek Y: Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum 58: 119-129, 2008.
14. Wasserman V, Kizelsztein P, Garbuzenko O, Kohen R, Ovadia H, Tabakman R and Barenholz Y: The antioxidant tempamine: in vitro antitumor and neuroprotective effects and optimization of liposomal encapsulation and release. Langmuir 23: 1937- 1947, 2007.
15. Yang XJ, Zhao XB, Phelps MA, Piao LZ, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC Dalton JT and Lee RJ: A novel liposomal formulation of flavopiridol. Int J Pharm 365: 170-174, 2009.
16. Fritze A, Hens F, Kimpfler A, Schubert R and Peschka-Süss R: Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta 1758: 1633-1640, 2006.
17. Ratnakumari A, Rajeswari A and Sobha K: A specific and sensitive assay for gefitinib using methods in pharmaceutical dosage forms. Pharmanest 1: 118-122, 2010.
18. Liu JB, Lee HL, Huesca M, Young AP and Allen C: Liposome formulation of a novel hydrophobic aryl-imidazole compound for anticancer therapy. Cancer Chemother Pharmacol 58: 306- 318, 2006.
19. Liu J, Xiao Y and Allen C: Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci 93: 132-143, 2004. (Pubitemid 38081821)
20. Wang S, Guo P, Wang X, Zhou S and Gallo JM: Preclinical pharmacokinetic/ pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 7: 407-417, 2008. (Pubitemid 351302534)
21. Challa R, Ahuja A, Ali J and Khar RK: Cyclodextrins in drug delivery: An updated review. AAPS Pharm Sci Tech 6: 329-357, 2005.
22. Miyake K, Irie T, Hirayama F, Uekama K, Hirano M and Okamoto Y: Characterization of itraconazole/2-hydroxypropyl-β-cyclodextrin inclusion complex in aqueous propylene glycol solution. Inter J Pharmaceut 179: 237-245, 1999. (Pubitemid 29131433)
23. Szente L and Szejtli J: Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliver Rev 36: 17-28, 1999. (Pubitemid 29074474)
24. Rasheed A, Kumar A and Sravanthi V: Cyclodextrins as drug carrier molecule: A review. Scientia Pharmaceutica 76: 567-598, 2008.